Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

859
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
859
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

929
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
929
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

8.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
8.4K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nesfatin-1 mitigates calcium oxalate nephropathy in mice through GPR12 receptor modulation and PKCα/NADPH oxidase pathway inhibition.

Life sciences·2026
Same author

Nesfatin-1 attenuates renal interstitial fibrosis, oxidative stress, and inflammation through dual suppression of TGF-β1/Smad and NF-κB/GPR12 signaling.

Biochemical pharmacology·2026
Same author

SOD1 and SOD2 gene variants are significantly correlated with male infertility in a North Indian population, suggesting a possible pleiotropic conflict.

Reproduction, fertility, and development·2026
Same author

Angiotensin II-induced fibrosis is mediated by activation of FGFR1 pathway in renal epithelial cells: Attenuation by chimeric peptide.

European journal of pharmacology·2025
Same author

From cells to systems: A comprehensive perspective on In-Vitro, In-Vivo, and 3D culture models of heart failure.

European journal of pharmacology·2025
Same author

Nucleobindin-2 Derived Multifunctional Peptide Nesfatin-1: Renoprotective Mechanisms and Therapeutic Promise.

Journal of biochemical and molecular toxicology·2025
Same journal

Fentanyl and its Analogs: A Medicinal Chemistry Perspective on Therapeutic Potential and Abuse Liability.

Current pharmaceutical design·2026
Same journal

Acne Vulgaris: Integrating Pathophysiology with Conventional, Herbal, and Nanocarrier-Based Therapeutic Strategies.

Current pharmaceutical design·2026
Same journal

Systems Pharmacology and Pharmaco-Transcriptomic Insights into Bauhinia variegata for Polycystic Ovary Syndrome Management.

Current pharmaceutical design·2026
Same journal

Curcumin and Cognitive Health: Insights from Randomized Controlled Trials.

Current pharmaceutical design·2026
Same journal

Inorganic Materials-integrated Porphyrin for Drug Delivery in Cancer Therapy: Promises, Challenges and Outlooks.

Current pharmaceutical design·2026
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
See all related articles

Related Experiment Video

Updated: Mar 30, 2026

Floral-Dip Transformation of Flax Linum usitatissimum to Generate Transgenic Progenies with a High Transformation Rate
08:49

Floral-Dip Transformation of Flax Linum usitatissimum to Generate Transgenic Progenies with a High Transformation Rate

Published on: December 19, 2014

30.1K

Flaxseed and Diabetes.

Kailash Prasad1, Arti Dhar

  • 1Department of Physiology College of Medicine University of Saskatchewan 107 Wiggins Road Saskatoon, Saskatchewan, Canada S7N 5E5. k.prasad@usask.ca.

Current Pharmaceutical Design
|November 13, 2015
PubMed
Summary
This summary is machine-generated.

Secoisolariciresinol diglucoside (SDG) from flaxseed shows potential in preventing type 1 diabetes and delaying type 2 diabetes. SDG treatment significantly reduced diabetes incidence in animal models by decreasing oxidative stress.

More Related Videos

Environmentally Induced Heritable Changes in Flax
08:10

Environmentally Induced Heritable Changes in Flax

Published on: January 26, 2011

10.7K
Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
05:49

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

5.6K

Related Experiment Videos

Last Updated: Mar 30, 2026

Floral-Dip Transformation of Flax Linum usitatissimum to Generate Transgenic Progenies with a High Transformation Rate
08:49

Floral-Dip Transformation of Flax Linum usitatissimum to Generate Transgenic Progenies with a High Transformation Rate

Published on: December 19, 2014

30.1K
Environmentally Induced Heritable Changes in Flax
08:10

Environmentally Induced Heritable Changes in Flax

Published on: January 26, 2011

10.7K
Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
05:49

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

5.6K

Area of Science:

  • Nutritional Science
  • Endocrinology
  • Biochemistry

Background:

  • Flaxseed is rich in oil and lignans, notably secoisolariciresinol diglucoside (SDG).
  • Oxidative stress is a key factor in the development of type 1 and type 2 diabetes.
  • Previous research indicates flaxseed components, particularly SDG, possess antioxidant and hypoglycemic effects.

Purpose of the Study:

  • To investigate the potential of flaxseed components, specifically SDG, in preventing type 1 diabetes and delaying type 2 diabetes.
  • To evaluate the impact of SDG on oxidative stress markers and glycemic control in diabetes models.

Main Methods:

  • Utilized animal models for type 1 diabetes (streptozotocin-induced and BBdp rats) and type 2 diabetes (ZDF rats).
  • Administered SDG and monitored serum glucose levels, malondialdehyde (MDA) as an oxidative stress marker, and glycated hemoglobin A1C.

Main Results:

  • SDG treatment reduced diabetes incidence by 75% in the streptozotocin model and 72% in the BBdp rat model.
  • Reductions in diabetes incidence were correlated with decreased serum and pancreatic MDA levels.
  • SDG delayed type 2 diabetes development in ZDF rats, associated with reduced serum MDA and glycated hemoglobin A1C.

Conclusions:

  • Secoisolariciresinol diglucoside (SDG) demonstrates significant potential in reducing type 1 diabetes incidence.
  • SDG may play a role in delaying the onset and progression of type 2 diabetes.
  • The anti-diabetic effects of SDG are likely linked to its ability to mitigate oxidative stress.